152 related articles for article (PubMed ID: 9303419)
21. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
22. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Gao J; Richardson DR
Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs.
Buss JL; Neuzil J; Ponka P
Arch Biochem Biophys; 2004 Jan; 421(1):1-9. PubMed ID: 14678779
[TBL] [Abstract][Full Text] [Related]
24. Effect of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture.
Richardson D; Baker E; Ponka P; Wilairat P; Vitolo ML; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):81-8. PubMed ID: 3390577
[No Abstract] [Full Text] [Related]
25. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
Richardson DR
Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
[TBL] [Abstract][Full Text] [Related]
26. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
27. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
Ponka P; Grady RW; Wilczynska A; Schulman HM
Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
[TBL] [Abstract][Full Text] [Related]
28. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.
Hermes-Lima M; Ponka P; Schulman HM
Biochim Biophys Acta; 2000 Oct; 1523(2-3):154-60. PubMed ID: 11042379
[TBL] [Abstract][Full Text] [Related]
29. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
30. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
31. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
Vitolo ML; Clare BW; Hefter GT; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
[No Abstract] [Full Text] [Related]
32. Replacement of transferrin in serum-free cultures of mitogen-stimulated mouse lymphocytes by a lipophilic iron chelator.
Brock JH; Stevenson J
Immunol Lett; 1987 May; 15(1):23-5. PubMed ID: 3610230
[TBL] [Abstract][Full Text] [Related]
33. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes.
Ponka P; Schulman HM; Wilczynska A
Biochim Biophys Acta; 1982 Oct; 718(2):151-6. PubMed ID: 7138909
[TBL] [Abstract][Full Text] [Related]
34. EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on *OH formation by the Fenton reaction.
Hermes-Lima M; Santos NC; Yan J; Andrews M; Schulman HM; Ponka P
Biochim Biophys Acta; 1999 Feb; 1426(3):475-82. PubMed ID: 10076064
[TBL] [Abstract][Full Text] [Related]
35. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity.
Richardson DR; Bernhardt PV
J Biol Inorg Chem; 1999 Jun; 4(3):266-73. PubMed ID: 10439071
[TBL] [Abstract][Full Text] [Related]
36. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
[TBL] [Abstract][Full Text] [Related]
37. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia.
Richardson DR
Leuk Lymphoma; 1998 Sep; 31(1-2):47-60. PubMed ID: 9720714
[TBL] [Abstract][Full Text] [Related]
38. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Apr; 131(4):306-15. PubMed ID: 9579383
[TBL] [Abstract][Full Text] [Related]
39. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients.
Edward JT; Chubb FL; Sangster J
Can J Physiol Pharmacol; 1997 Dec; 75(12):1362-8. PubMed ID: 9534947
[TBL] [Abstract][Full Text] [Related]
40. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
